Typhlitis as a complication of alemtuzumab therapy.
نویسندگان
چکیده
Alemtuzumab is a humanized monoclonal antibody directed against lymphocytes through the CD-52 receptor, an antigen being found on > 95% of peripheral blood lymphocytes and monocytes, and to a smaller extent on granulocytes. It is an effective immunotherapeutic agent in patients with malignancies such as non-Hodgkin lymphoma, B cell chronic lymphocytic leukemia and T cell pro- lymphocytic leukemia. Adverse side effects are increasingly recognized in patients receiving alemtuzumab, mainly including fever, rigors, nausea/vomiting, skin rash; other severe alemtuzumab-related reactions have also been described, such as lymphopenia and neutropenia leading to both opportunistic (e.g. cytomegalovirus) and non-opportunistic infections. Digestive complications have more rarely been described, i.e.: gastroenteritis and peritonitis. We recently observed a case of particular interest as the patient with T cell prolymphocytic leukaemia treated with alemtuzumab, exhibited symptomatic reactivation of CMV infection and developed subsequently typhlitis.
منابع مشابه
Typhlitis in a post-chemotherapy lymphoma patient; images in clinical medicine
Typhlitis, also known as neutropenic enterocolitis, occurs primarily in severely immunosuppressed patients undergoing chemotherapy for haemathological and solid tumors. We report a case of a 57 years-old patient who presented typhlitis as a complication during chemotherapy.
متن کاملMortal neutropenic enterocolitis in acute lymphoblastic leukemia
Neutropenic enterocolitis (NE) or typhlitis is a serious complication of anticancer therapy, especially in hematological malignancies. We describe a case of acute lymphoid leukemia presenting the early onset of a syndrome with the clinical features and specific radiological findings of NE during the neutropenic phase.
متن کاملTyphlitis: a neutropenic complication.
DESCRIPTION ‘Typhlitis’ describes enterocolitis of the ileocaecal region seen commonly in neutropenic patients. As compared with other malignant conditions, acute myeloid leukaemia (AML) is most often associated with typhlitis. The pathogenesis of typhlitis probably involves a combination of factors, including mucosal injury by cytotoxic drugs, profound neutropenia and impaired host defence to ...
متن کاملLong-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab.
CD52 is expressed on malignant cells in lymphoplasmacytic lymphoma (LPL), including IgM-secreting Waldenström macroglobulinemia (WM). We examined the activity of alemtuzumab in 28 symptomatic LPL (27 IgM and 1 IgA) patients. The median prior number of therapies for these patients was 2 (range, 0-5) and 43% had refractory disease. Patients received alemtuzumab at 30 mg IV 3 times weekly for up t...
متن کاملAlemtuzumab: what is the secret to safe therapy?
Over the past decade, the use of the monoclonal antibody alemtuzumab in chronic lymphocytic leukemia has expanded from administration as a single-agent therapy, into use in combination with fludarabine or rituximab, and further to use as a consolidation agent with the goal of eradicating minimal residual disease. Numerous clinical studies have shown that alemtuzumab is effective as first-line t...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Haematologica
دوره 92 5 شماره
صفحات -
تاریخ انتشار 2007